Mumbai, 17th April, 2025: Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbamazepine Tablets USP, 200 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Tegretol Tablets, 200 mg, of Novartis Pharmaceuticals […]
The post Alembic Pharmaceuticals Secures USFDA Final Approval for 200 mg Carbamazepine Tablets first appeared on Business News Week.
Comments are closed